Indaptus Therapeutics, Inc.
Indaptus Therapeutics is an emerging leader in the immunotherapy space, focused on advancing a pre-clinical pipeline of therapeutic candidates designed to elicit broad and durable anti-tumor and anti-viral responses to cure disease. The company harnesses both innate and adaptive immune responses by exploiting bacteria’s natural ability to activate immune pathways, creating proprietary, attenuated, and killed non-pathogenic gram-negative bacteria with broad anti-tumor and anti-viral activity. They are developing and advancing a pipeline of these bacterial candidates, including their lead candidate Decoy20, which has demonstrated activity in pre-clinical models and is in Phase 1 clinical trials. The company is headquartered in New York City and trades on the Nasdaq under the symbol INDP.
Industries
Nr. of Employees
small (1-50)
Indaptus Therapeutics, Inc.
Patents
Accordion pill comprising levodopa for an improved treatment of Parkinson's Disease symptoms
US-9801826-B2
View Details
Accordion pill comprising levodopa for an improved treatment of Parkinson's Disease symptoms
US-9801826-B2
View DetailsProducts
Attenuated/killed gram-negative bacterial therapeutic candidates (lead advanced to Phase 1)
A pipeline of attenuated and killed non-pathogenic gram-negative bacterial candidates developed to engage innate and adaptive immunity for anti-tumor and anti-viral effects. Reported preclinical attributes include activity in multiple tumor models, synergy with other therapy classes, induction of immunological memory, and GMP manufacturing for clinical use.
Attenuated/killed gram-negative bacterial therapeutic candidates (lead advanced to Phase 1)
A pipeline of attenuated and killed non-pathogenic gram-negative bacterial candidates developed to engage innate and adaptive immunity for anti-tumor and anti-viral effects. Reported preclinical attributes include activity in multiple tumor models, synergy with other therapy classes, induction of immunological memory, and GMP manufacturing for clinical use.
Expertise Areas
- Bacterial immunotherapy development
- Immuno-oncology preclinical development
- Combination therapy evaluation
- Preclinical safety and toxicity assessment
Key Technologies
- Attenuated/killed gram-negative bacterial immunotherapy platform
- In vivo tumor models (xenograft and syngeneic)
- Preclinical combination therapy evaluation
- Assays for innate and adaptive immune activation and memory
News & Updates
Webcast link for the Jefferies Global Healthcare Conference scheduled for June 4-6, 2024.
Intec Pharma Ltd., a biopharmaceutical company, will visit the Nasdaq MarketSite in Times Square in observance of World Parkinson’s Day. Jeffrey A. Meckler, CEO, will ring the Closing Bell.
Webcast link for the Jefferies Global Healthcare Conference scheduled for June 4-6, 2024.
Intec Pharma Ltd., a biopharmaceutical company, will visit the Nasdaq MarketSite in Times Square in observance of World Parkinson’s Day. Jeffrey A. Meckler, CEO, will ring the Closing Bell.